Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to collaborate on up to seven programs built on technology for targeting ...

Vertex Pharmaceuticals is different from Novo Nordisk in several ways. The two companies could compete against each other in the future. Vertex is a better pick than Novo right now for one key reason.

Ozempic maker Novo Nordisk on Wednesday said data showed its hotly anticipated weight loss pill prompts greater and more rapid weight loss than its blockbuster treatment Wegovy, amid competition ...

Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...

While Novo is struggling to keep up with demand for its obesity drugs, U.S. rival Eli Lilly sees supply restraints easing.

Novo Nordisk has been slowly increasing production capacity of its highly coveted weight loss drugs. As a result, thousands of people have began treatment per week. Wegovy has been FDA-approved ...